drugset / Trial / NCT02428855
Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
Phase 2
Completed
8 enrolled
Massachusetts General Hospital
Bristol-Myers Squibb · collabTargetCancer Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying Dasatinib as a possible treatment for cancer of bile ducts.
Timeline
- Start
- 2015-04
- Primary completion
- 2018-02
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | — | Oral |